Biofortuna has provided assay development and manufacturing support to QuantuMDx Group Limited to assist in the manufacturing scale-up, regulatory approval and launch of their rapid, sensitive SARS-CoV-2 test.
In light of the current situation with COVID-19, we would like to take this opportunity to assure you that plans have been put into place to ensure business continuity at Biofortuna.
Having developed over 100 assays across a range of diverse applications, let Biofortuna be your outsourcing partner of choice. Our FDA registered and ISO 13485 certified manufacturing facilities allow us to take your project from concept through to full commercial production and to market. Contact us now to discuss your requirements.
Biofortuna (Liverpool, UK) – the international IVD contract research and contract manufacturing company – will be launching ampDRY™, its patent pending stabilised master mix for PCR applications, at the AACC Annual Scientific Meeting and Clinical Lab Expo in Chicago, July 29 to August 2. ampDRY hotstart master mix has been developed to enable complete end-stage or real-time PCR assays to
Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has raised £1.6M in its latest funding round. The new funding –supported by current investor Foresight VCTs and members of the senior management team – will allow the company to take its ReadyPlex™ rapid blood group genotyping assays into clinical trials and commercialisation, as well as
Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits. Biofortuna already has extensive experience in immunoassay development, and this expansion has been driven
Biofortuna have successfully completed an FDA site inspection to retain their FDA registered manufacturing site status. The inspection was carried out over several days in which the FDA thoroughly reviewed Biofortuna’s manufacturing, quality control and quality assurance procedures. Biofortuna manufactures 510k approved IVD kits for sale in the US for their molecular diagnostics division. An increasing number of contract service
Biofortuna Ltd is pleased to announce a record year of growth for its IVD Contract Services division. This growth has been driven by the expansion of its service portfolio, together with increased demand for its core lyophilisation services. Biofortuna’s success stems from its specialist freeze-drying expertise and proprietary cryopreservation technologies, allowing the stabilisation of complete PCR, isothermal amplification and immunoassay
Biofortuna Ltd, a diagnostics company based in Wirral UK, announces significant investment into its IVD Contract Manufacturing Division in order to support continued growth. Biofortuna’s new climate control system will allow for accurate control of environmental factors down to 5% relative humidity, resulting in unrivalled stability of lyophilised reagents. Packing in a low humidity environment ensures products are stored under
Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market. World-renowned for its lyophilisation services and molecular diagnostic products, Biofortuna has developed a new internal infrastructure, creating distinct products and services divisions and giving the company